On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
NNW Headlines
Save 20% on Press Releases and More with NNW Prime! Click to View Details
Home » Archives for July 2021 » Page 15

Month: July 2021

ThursdayJul 01, 2021 11:18 am

SRAX Inc.’s (NASDAQ: SRAX) Premier Investor Real-Time Analytics Platform, Sequire, Helping 180+ Public Companies Track 5M+ Investors

SRAX’s Sequire SaaS platform provides tools to help public companies track shareholders, manage warrants, issue shareholder surveys SRAX recently featured in Wall Street Journal article highlighting volatility problems for public companies Sequire subscriber base doubled between Q3 and Q4 2020 to 183 public companies across 5 million+ active traders, investors SRAX (NASDAQ: SRAX), a financial technology company, helps publicly traded companies unlock data and insights with Sequire, its SaaS investor analytics platform that features a unique set of tools that allows users to track investors, manage warrants, publish news and issue surveys. Since its creation in 2019, the platform has…

Continue Reading

ThursdayJul 01, 2021 9:00 am

Friendable Inc.’s (FDBL) Fan Pass Live Helping Music Industry Overcome Pandemic Challenges, Offering New Opportunities for Artists

Friendable’s Fan Pass platform has provided revenue streams for artists that may not have existed due to the global pandemic Version 2.0 of the Fan Pass artist streaming platform to be released on July 24, 2021, which also marks the first anniversary of the platform Friendable has signed a Letter of Intent for the production of musical-artist NFTs and the creation of a “Fanpasscrypto” marketplace The global music streaming market was valued at $24.4 billion in 2020 and is expected to grow by a CAGR of 17.8%, resulting in $76.9 billion in revenue by 2027 (https://nnw.fm/Bstdt). The increase is largely…

Continue Reading

ThursdayJul 01, 2021 9:00 am

Infobird Co. Ltd. To Expand Its Chinese Frontiers By Launching the Next Generation Of SaaS

Infobird is launching the Next Generation of SaaS in China to grab a massive share of the massive and growing cloud infrastructure market The company is leveraging the huge growth opportunity represented by the boom of cloud infrastructure triggered by the shift towards cloud computing by businesses Inforbird is one of the few SaaS companies that can serve SMEs with its no-code development platform Infobird (NASDAQ: IFBD) is a business-to-business (“B2B”) artificial intelligence (“AI”) solutions company, focused on developing AI-driven customer engagement solutions, especially for the finance segment. A premier provider of customer engagement software-as-a-service (“SaaS”) solutions in China, the company…

Continue Reading

ThursdayJul 01, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Announces Status Report on Six Key R&D Programs

Lexaria announced significant strides in six of its studies within the 2021 applied R&D program1 All the studies are based on Lexaria’s DehydraTECH(TM) technology and are designed for multiple market applications, including oral nicotine, NSAIDs, antivirals, and hypertension The 2021 applied R&D program is intended to generate not only confirmatory results and data evidencing but also foster strategic commercial opportunities and corporate relationships Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX) released a status report on six of its studies in the 2021 applied research and development (“R&D”) program. The program mainly involves studies using DehydraTECH(TM) 2.0 formulations, with different market areas…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217

NetworkNewsWire

8033 Sunset Blvd Suite 1037
Los Angeles, CA 90046
(212) 418-1217

Copyright . NetworkNewsWire® / 8033 Sunset Blvd Suite 1037 Los Angeles, CA 90046 (212) 418-1217 / Disclaimers